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ABSTRACT
Objective: The current research deals with the formulation and evaluation of synthesized quinazolinone derivative for colon site specific delivery.
Methods: The synthesized quinazolinone derivative was enteric coated 5% Eudragit L-100 with by wet granulation method using guar gum, pectin, 
and guar gum pectin combination as hydrophilic polymer. The prepared matrix tablet was characterized by differential scanning calorimetry and 
evaluated for different pre-compression and post-compression studies and drug release profiles.
Results: All the matrix tablets were within the range of pharmacopeial limits with better flow properties. All the six formulations of matrix tablets had 
disintegrated within 5-6 minutes. The optimized formulation selected was F6 formulation combination of guar gum and pectin with 95.79% of drug 
release than compared to the remaining formulation. The optimized matrix tablets followed zero order kinetics with Fickian diffusion.
Conclusion: The results proposed that the combination of guar gum and pectin coated tablet with 5% Eudragit L-100 of synthesized quinazolinone 
derivative is a promising colon site specific delivery.
Keywords: Quinazolinone derivative, In vitro drug release, Disintegration time, Guar gum, Pectin, 5% Eudragit L-100, Colon site-specific delivery, Wet 
granulation, Compression.
INTRODUCTION
From the last 20 years, an intensive quantity of analysis work has been 
administered within the space for colon site specific delivery attributed 
to its macromolecule and amide medicine that reduces the adverse 
effects within the treatment of colonic diseases, so minimizing the 
intensive first pass metabolism of steroids and produces delayed drug 
absorption for the treatment of atrophic arthritis, angina and nocturnal 
bronchial asthma, etc. [1].
One of the approaches we tend to suggests within the advancement of 
colon specific delivery is the advantage of 7-chloro-3-(4-chlorophenyl)-
2-phenyl quinazolin-4(3H)-one derivative for colon delivery. The 
synthesized 7-chloro-3-(4-chlorophenyl)-2-phenyl quinazolin-4(3H)-
one derivative belongs to heterocyclic category of compounds exhibiting 
medicine and biological activities [2]. 7-chloro-3-(4-chlorophenyl)-2-
phenyl quinazolin-4(3H)-one inhibits thymidylate synthase receptor 
preventing the expansion of cancerous cells. It is been aimed towards 
designing a pH dependent polymer matrix tablets of 7-chloro-3-(4-
chlorophenyl)-2-phenyl quinazolin-4 (3H)-one in consideration with 
minimizing the drug release within the biological surroundings of 
stomach and intestine associated to confirm the major drug release 
within the colon resulting in better patient approval, higher drug 
therapy and all advantages of an efficient colon specific delivery [3-7]. 
The colon is attracting interest attributable to its longer retention time 
due to its ability to reinforce the absorption of lipophilic drugs. Oral 
administration primarily depends on the chemical science properties 
of the drug, and therefore, the nature of the compound. Hydrophilic 
polymers play a key role in formulating oral controlled release tablets 
attributable to its chemical compound material that swells, and 
therefore, the drug releases by diffusion [8]. Many polysaccharides 
such as chondroitin salt, xanthan gum, guar gum, cellulose, and enzyme 
had been studied for providing higher potency in colon delivery. Pectin 
and guar gum are refractory to gastric and intestinal enzymes but are 
completely degraded by the colonic microorganism enzymes to provide 
soluble oligogalacturonides. The aim of this study was to prepare 
colon site-specific tablets of 7-chloro-3-(4-chlorophenyl)-2-phenyl 
quinazolin-4 (3H)-one using Guar gum and pectin as matrix polymer 
that provides protection to the drug till it leaves the abdomen that is 
provided by pH scale dependent polymer, Eudragit L 100 and major 




Guar gum, pectin, microcrystalline cellulose (MCC), croscarmellose 
sodium, sodium starch glycollate, talc, magnesium stearate, Polaxamer 
407, Eudragit L-100 were purchased from Nice Chemicals Pvt. Ltd. 
Kochi.
Methods
Preparation and characterization of synthesized quinazolinone 
matrix tablets
Wet granulation technique was used for the preparation of synthesized 
quinazolinone matrix tablets using hydrophilic polymer (guar gum, 
pectin and combination) as matrix forming agent in the ratio of 1:3 
and 1:5 with 5% Eudragit L-100 for enteric coating. All the ingredients, 
i.e., quinazolinone, MCC, croscarmellose sodium were mixed vigorously 
in a mortar and pestle. The powdered ingredients were allowed to dry 
at 60°C before sieve through 16#. The granules then passed through 
sieve no. 22#. Finally, the granules were lubricated with talc, aerosil 
and magnesium stearate. The characterization of prepared matrix 
tablet was done by differential scanning calorimetry (DSC) [15,16]. The 
composition of the matrix tablet was represented in Table 1.
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Precompression parameters
Precompression parameters include the determination of bulk density, 
tapped density, compressibility no comma after compressibility 
index, and Hausner’s ratio. Weighed amount of 10 g of granules were 
transferred into a 100 ml measuring cylinder. Initial volume was noted 
before 100 times tapping. The final volume was measured. Bulk density, 
tapped density, compressibility index (Carr’s index), and Hausner’s 
ratio were calculated. A funnel was placed fixed to a height and 10 g of 
powder was added through it. The tip of the funnel should be adjusted 
so that it touches the powder heap [16-19].
Bulk density (Vb)=Mass/bulk volume
Tapped density (Vtb)=Mass/tapped volume
Hausner’s ratio=Tapped density/bulk density
Carr s index







Monsanto hardness tester was used to measure the strength of 
the matrix tablet. It consists of a lower plunger which was kept in 
contact with the tablet. The thunderbolt of the plunger has been 
tuned before zero reading by forcing against a plunger until the 
tablet ruptured. The force applied was detected by a barrel when 
the spring has been compressed. Randomly selected tablets were 
selected to measure the mean and standard deviation values were 
calculated [20-25].
Friability test
About 10 tablets were weighed and placed in Roche friability chamber 
which was allowed for 100 revolutions to attain effects of abrasion and 
shock because the tablet drops by six inches from the chamber. The 
tablets were re-weighed [20-24].
% Friability 
Initial weight of tablet Final weight of tab
=
− lets
Initial weight of tablets
×100
Thickness of tablets
Calibrated screw gauge was used to measure the thickness of the tablet. 
The value of the prepared matrix tablet should be such that each tablet 
must deviate from ±5 of the standard value [20-24].
Weight variation test
About 20 tablets were randomly selected, and the average weight of 
each tablet was noted to compare with the individual weight of each 
tablet as described by IP was followed [20-24].
Percentage deviation = (X-X٭/X)×100
Where,
X - Actual weight of the tablet
X٭ - Average weight of the tablet.
Drug content
About 20 tablets were powdered and weighed. The powder was then 
dissolved in ethanol and made up to 100 ml. The solution was mixed 
well and filtered. To make the solution up to a desired concentration, 
the solution was then diluted with each 10 ml of the prepared solution 
with ethanol. The absorbance of the resulting solution was measured 
using ultraviolet (UV) spectrophotometer [20-24,26].
% Drug content  
Actual quinazolinone content in weight quantity matrix tablet 100
Theoretical amount of quinazolinone in matrix tablet

×
Evaluation of matrix tablets
In vitro disintegration studies
Disintegration apparatus consist of six test tubes in which one tablet was 
placed in each of six test tubes which were immersed in a 1 L beaker in 
the basket containing pH 6.8 buffer solution maintained at 37±0.5°C in 
such a way that the tablet settles 2.5 cm lower to the surface of the liquid. 
The time at which the tablet completely disintegrates was noted [27].
In vitro dissolution studies
USP Type II (paddle type) dissolution test apparatus was used to study 
the drug release for all the six formulations. The tablet has been placed 
in a beaker attached to a paddle containing 900 mL dissolution medium. 
The apparatus was maintained at 37±0.5°C, 100 rpm. At first, the tablet 
has been placed in pH 1.2 which was then replaced with pH 7.4 and 
pH 6.8 after 2 hrs as the average gastric emptying time. At each time 
interval of 2, 5, 6, 8, 10, 12, 14, 16, 18, 20 and 24 hrs. 5 ml of the sample 
was pipetted out with the same amount been replaced with dissolution 
media to attain sink condition. The withdrawn samples were analyzed 
from the absorption maxima by UV spectroscopy, and the release kinetics 
were studied by fitting the data in different kinetic models [28-30].
Stability studies
The prepared matrix tablet was tested for stability study based on 
ICH guidelines. The stability condition was maintained under two 
temperature: At room temperature 30±2°C and 65±5°C relative 
humidity (RH) and accelerated conditions 40±2°C and 75±5°C RH in 
a stability chamber. The samples were collected at regular intervals 
of 0, 2, 3 and 6 months and tested for visual assessment such as 
appearance and weight variation, hardness, thickness, friability, and 
drug content [31-33].
RESULTS AND DISCUSSIONS
Characterization of synthesized quinazolinone matrix tablets
The DSC thermograph of quinazolinone derivative in (Fig. 2) showed 
four endothermic peak at 60.14, 84.68, 140.11 and 239°C. The first 
peak indicates guar gum since their value corresponds to their melting 
point. The melting point 239°C indicate the compound and the one 
with 140.11°C indicate the presence of pectin. The result shows the 
presence of both the compound and the polymer indicating that the 
pure compound changed to amorphous form. The photograph of the 
prepared matrix tablet is represented in Fig. 1.
Precompression studies
From the results, the bulk density values indicate to be significant since 
the density were <1.2 g/cm3. From the experiments, the angle of repose 
for all the six formulations were <40° indicating good flow property. 
The compressibility index and Hausner’s ratio for the granules also 
specify good flow properties of the powders. All the data obtained were 
compared with the standard criteria as revealed in IP with efficient flow 
properties and better compressibility for all the formulated tablets. The 
results were given in Table 2.
Postcompression studies
The various batches of the tablet hardness were found to be within limits 
indicating good tablet strength. It was observed that the hardness of the 
Table 1: Composition of synthesized quinazolinone matrix 
tablet
S. No. Ingredients Quantity (mg)
1 QD-synthesized quinazolinone 200
2 MCC 64
3 Sodium starch glycollate 10
4 Croscarmellose cellulose 6
5 Aerosil 4
6 Talc 3
7 Magnesium stearate 3
MCC: Microcrystalline cellulose
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stability with no broken tablets. The average weight of all the matrix 
tablet was in the range of 2.84±1.06-3.56±0.89 mg. The results of 
variation were <7.5% within the pharmacopoeial limits indicating its 
uniformity with low standard deviation values. Drug content of the 
tablets was within 98.57±0.83-98.76±1.52 which significantly approves 
the homogeneity of the drug and excipients. The results were given in 
Table 3.
In vitro disintegration study
In vitro disintegration studies were carried out for the matrix tablets. All 
the tablets were disintegrated within 5.21±0.014-6.47±0.011 minutes. 
The disintegration time for six formulations were shown in Table 4.
In vitro drug release study
For the productive delivery of drugs to the colon needs coating of 
drug from being released in abdomen and small intestine; hence the 
compression coated tablets were enteric coated to forestall the drug 
release in higher a part of stomach.
•	 All	 the	 tablets	 compression-coated	with	pH-dependent	polymers	
(Eudragit L-100) showed low release percentage in 0.1 N HCl for 2 
hrs once the solution was replaced with phosphate buffer pH 7.4 for 
another 3 hrs, F1 coated with Eudragit L100 exhibited the quickest 
release. It released 18.94% drug release of the drug in 3 hrs. On 
tablets was found within 4.23±1.48-5.61±1.54 kg/cm2. The satisfactory 
crushing strength considered to be 4 kg for tablet. The thickness of 
tablets was found to be in the range of 4.21±0.65-4.39±0.68 mm, 
respectively, which indicates its uniformity in all the formulations. The 
tablets friability considered to be satisfactory since the ranges were 
observed from 0.56±0.37 to 0.69±0.34% indicating its mechanical 
Fig. 1: Photograph of prepared matrix tablet
Fig. 2: Differential scanning calorimetry of prepared matrix tablet
Table 2: Precompression studies for the prepared matrix tablet
Formulation code Angle of repose (°) Bulk density (g/cc) Tapped density (g/cc) Carr’s index (%) Hausner’s ratio
F1 28.15±1.04 0.584±0.013 0.606±0.018 10.05±0.58 1.034±0.010
F2 29.86±1.06 0.587±0.010 0.610±0.017 9.12±0.54 1.038±0.012
F3 28.23±1.07 0.575±0.014 0.595±0.019 9.84±0.63 1.036±0.015
F4 29.25±1.08 0.589±0.015 0.613±0.013 10.39±0.52 1.047±0.011
F5 27.94±1.04 0.590±0.013 0.617±0.017 10.14±0.67 1.045±0.015
F6 28.36±1.02 0.588±0.015 0.616±0.017 10.06±0.67 1.036±0.014
All values are expressed in mean±standard deviation, n=3
Table 3: Postcompression studies for the prepared matrix tablet
Formulation code Hardness (kg/cm2) Thickness (mm) Friability (%) Weight variation (mg) Drug content (%)
F1 4.98±0.98 4.21±0.65 0.67±0.39 3.49±0.88 98.76±1.52
F2 4.23±1.48 4.25±0.54 0.69±0.34 3.56±0.89 97.81±1.22
F3 5.61±1.54 4.37±0.62 0.56±0.37 3.48±1.06 97.85±0.98
F4 4.42±0.85 4.28±0.49 0.63±0.38 2.99±1.08 98.57±0.83
F5 5.33±0.99 4.39±0.68 0.58±0.28 3.24±1.06 98.67±1.50
F6 5.22±1.78 4.22±0.52 0.59±0.26 2.84±1.06 97.87±0.96
All values are expressed in mean±standard deviation, n=3
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the other hand, F6 coated with Eudragit L-100 showed the slowest 
release in this medium where it released solely 0.64% release. The 
total percentage of the drug released in F1, F2, F3, F4, F5 and F6 were 
78.43%, 81.68%, 83.29%, 83.29%, 86.68%, 93.66% and 95.79% 
release, respectively, after the 24 hrs of the release study. Therefore, 
Eudragit L-100 prevents the release of the drug into stomach and 
small intestine by degrading the polymer into the microorganism 
enzymes of colon.
The formulations of different matrix tablets containing guar gum 
(1:3, 1:5)
A maximum release of 71.43% and 73.66% drug release were shown 
by formulation F1 and F2 respectively. In case of tablet formulated with 
guar gum, F1 and F2 show 6.28% and 6.10% drug release for 2 hrs and 
18.94% and 14.27% within 5 hrs.
The formulations of two different matrix tablets containing for 
pectin (1:3, 1:5)
The cumulative percentage released was then plotted against time and 
maximum release of 81.29% and 84.68% were shown by F3 and F4, 
respectively. F4 using 1:5 drug polymer ratio showed better drug release 
when compared to F3. It has been noted that as the concentration of 
pectin decreases the rate and extent of drug release increased. Hydration 
and swelling of pectin or guar gum result in the formation of a viscous 
gel layer. This in turn slows down the dissolution from the core tablet. 
Mechanical erosion of the swollen polymer takes place when the tablet 
gets hydrated, and the drug release takes place by diffusion of tablet.
The formulations of different matrix tablets containing guar gum 
and pectin gum combination (1:3, 1:5)
A maximum release of 93.60% and 95.79% was shown by F5, F6, 
respectively. The extent of target area for the drug release is 5-24 hrs. 
As the combination of hydrophilic polymer hydrated more with the 
degradation of bacterial enzyme.
The optimized formulation selected was F6 formulation combination 
of guar gum and pectin since the drug release was found to be 95.79% 
Table 4: In vitro disintegration of matrix tablet







All values are expressed in mean±standard deviation, n=3
Table 6: Stability studied for optimized matrix tablets
Months Hardness (kg/cm2) Thickness (mm) Friability (% loss) Weight variation (%) Drug content (%)
2 7.8±0.30 3.64±0.18 0.48±0.16 347±0.40 98.57±0.28
3 7.8±0.21 3.63±0.24 0.48±0.17 347±0.30 98.57±0.30
4 7.7±0.35 3.65±0.20 0.47±0.20 345±0.22 98.57±0.36
5 7.7±0.32 3.66±0.18 0.46±0.18 345±0.30 98.54±0.30
6 7.7±0.31 3.65±0.21 0.46±0.18 345±0.40 98.54±0.30
All values are expressed in mean±standard deviation, n=3
Table 5: Drug release kinetics for optimized formulation
Formulation code Zero order R2 First order R2 Higuchi R2 Korsmeyer–peppas
n R2
F6 0.9881 0.9362 0.9657 0.4362 0.9499




Asian J Pharm Clin Res, Vol 10, Issue 3, 2017, 207-212
 Shammika et al. 
than compared to the remaining formulation. The release graph was 
represented in Fig. 3.
Mathematical modeling of kinetics
The kinetic modelling dissolution profile obtained were represented 
in Fig. 4 and the regression co-efficient  value for the optimized 
formulation were mentioned in Table 5. Based on the in vitro release 
dissolution profiles and various dissolution parameters the best 
drug release from the tablet were selected from the formulation. The 
optimized formulation selected was F6.
The drug release followed zero order kinetics with Fickian diffusion 
mechanism as the regression coefficient has been greater in zero order.
Stability studies
The optimized formulation was found to be more stable for a period 
of 6-month based on ICH guidelines. The stability study profile for the 
optimized formulations were done for 6 months were represented in 
Table 6.
CONCLUSION
The formulated quinazolinone matrix tablet consist of guar gum, pectin 
as a polymer enteric coated with Eudragit L100 with main focus onto 
the release of drug into the colon. All matrix tablets possessed good 
hardness, friability, compression, disintegration, and dissolution 
properties. The guar gum-pectin combination matrix tablets were found 
to be more efficient drug release into the colon as the concentration 
of guar gum-pectin increased the release of drug into the stomach and 
intestine is decreased.
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